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OBJECTIVES: To assess the cost-effectiveness of Rebif com-
pared to its comparators in the German health care setting in
2008. METHODS: A decision analysis model was used to esti-
mate the cost-effectiveness of Rebif in patients with relapsing-
remitting multiple sclerosis (RRMS). The analysis was based on
a comparison of treatment with Rebif (44 mcg tiw) versus all
other existing disease modifying drug (DMD) treatments from a
societal perspective: Avonex (30 mcg qw), Betaferon (8 MIU
qod), Copaxone (20 mg qd). Data sources used included pub-
lished literature, clinical trials, ofﬁcial German price/tariff lists
and national population statistics. The time horizon of the
model was four years, which is the maximum follow-up of
patients in published clinical trials with interferons. RESULTS:
The cost-effectiveness expressed in cost per relapse avoided is
€51,250 for Rebif, which compares favourably with the other
comparators. The cost per relapse avoided is €133,770 for
Avonex, €71,416 for Copaxone and €54,475 for Betaferon,
respectively. When cost of disease progression is excluded, the
cost per relapse avoided remains favourable for Rebif (€ 54,292)
compared with the other drugs (Avonex €143,186, Copax-
one €72,809, Betaferon €56,816). Sensitivity analyses varying
the discount rate, frequency of type of relapse, cost of relapse,
cost of disease progression and non-compliance have a minor
impact on the study outcomes. CONCLUSIONS: This study
provides evidence on the cost-effectiveness of ﬁrst-line treatment
options for multiple sclerosis in the German setting. In particu-
lar, we found that the cost-effectiveness associated with Rebif 44
was favourable compared to other DMDs, providing additional
value to payers.
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OBJECTIVES: To investigate the cost-effectiveness of aripipra-
zole compared to standard-of-care (SOC) in the Schizophrenia
Trial of Aripiprazole (STAR). METHODS: STAR was a multi-
centre, 26-week, randomised, naturalistic, open-label study com-
paring aripiprazole with SOC (deﬁned as clinician’s choice of
olanzapine, quetiapine or risperidone) in the management of
community-treated patients with schizophrenia (1). The primary
outcome in the cost-effectiveness analysis was the cost per unit of
improvement on the main clinical outcome in STAR, the Inves-
tigator’s Assessment Questionnaire (IAQ) (2). Secondary
outcome measures were the cost per additional CGI-I responder
and the cost per unit of improvement on the Quality of Life Scale
(QLS). Data on service use and employment were collected
alongside the trial. Statistical adjustment was made for baseline
characteristics on all outcomes. The perspective taken was that of
the NHS and social care in the UK. RESULTS: Aripiprazole was
associated with a signiﬁcantly better improvement on the IAQ
(p = 0.0002), the CGI-I response rate (p = 0.0080) and the QLS
scores (p = 0.0003) as compared to SOC. The improvement
observed in the QLS scores at six months in this study
approached that of clinical signiﬁcance at 1 year (3.4). The
incremental cost effectiveness ratio (ICER) for the IAQ was £714
per unit of improvement. We estimated that a clinically signiﬁ-
cant improvement would be an 8 point improvement in the IAQ
score. The cost per 1% increase in the number of CGI-I respond-
ers was £1413. Thus it would cost £1413 to go from 10 to 11
responders in a sample of 100 patients. The ICER for the QLS
suggests a cost of £288 for each unit of improvement gained.
CONCLUSIONS: Aripiprazole has shown to provide improve-
ments in effectiveness and quality of life at a reasonable cost
compared to SOC based on an economic analysis of a naturalistic
trial.
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OBJECTIVES: To assess the economic burden of moderate
Alzheimer’s Disease (AD) and to analyze the impact of depres-
sion, from the societal perspective. METHODS: IDEAL is an
epidemiological, prospective and multicentric study in which
1,071 patients from 180 investigators in Spain, with moderate
AD and available information on resources were assessed.
Resources consumption was assessed in a cross-sectional way at
the end of the study. The following resources were included in the
analysis: health care (medication: anti-Alzheimer, neuroleptics
and anti-depressive drugs) and non-health care direct costs
(formal care and social services: institutionalization and day care
center attendance) and indirect costs (caregivers loss of produc-
tivity). Costs are expressed in euros 2007. The cognitive and
functional status were measured by the Mini-Mental State
Examination (MMSE) and Barthel Index, respectively. Patients
were grouped taking into account the score obtained in the
depression Cornell Scale (cut-off-point: 8). RESULTS: Depres-
sion was present in 52% of the patients. The average monthly
cost per patient was €1043 and €653 in patients with and
without depression, respectively. Non-health care direct costs
and the caregivers loss of productivity were the most important
cost categories. In patients with depression, 56%, 34% and 10%
were attributable to non-health care direct costs, productivity
loss and drug costs, respectively. In comparison, in patients
without depression, the same distribution costs were 61%, 25%
and 14%. The cost of productivity loss is more than doubled in
the depression patient cohort. Patients with depression showed a
higher and signiﬁcant cognitive impairment, through MMSE
scores: 14.7 (4.7) in depressed patients and 15.2 (4.9) in
non-depressed patients. The same ﬁnding was observed in the
daily life activities measured by the Barthel Index: 68.2 (22.7)
and 81.1 (19.9) in patients with and withour depression. CON-
CLUSIONS: Adequate management of depression in patients
with moderate AD would have a positive impact on societal
resource consumption.
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OBJECTIVES: Compare annual direct costs (both total and
epilepsy-related) between privately insured U.S. epilepsy patients
and matched controls. METHODS: A total of 4323 patients with
greater than or equal to 1 epilepsy diagnosis (ICD-9-CM: 345.x),
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1999–2004, ages 16–64 years, were selected from a privately
insured claims database with 6+ million beneﬁciaries. Control
group was an age and gender matched cohort of randomly
chosen beneﬁciaries without epilepsy. All were required to have
continuous health coverage during 2004 (baseline) and 2005
(study period). Chi-squared tests were used to compare baseline
comorbidities. Wilcoxon rank-sum tests were used for univariate
comparisons of annual direct (medical and pharmaceutical) costs
to insurers during the study period. RESULTS: Patients with
epilepsy averaged 43 years old, and there were more females
(57%). Compared with controls, epilepsy patients had signiﬁ-
cantly higher rates of mental health disorders, comorbidities
included in the Charlson Comorbidity Index (e.g., cerebrovascu-
lar disease, congestive heart failure, COPD, rheumatologic
disease, cancer), migraine, and other neurological disorders. On
average, direct annual costs were signiﬁcantly higher for epilepsy
patients ($10,258) compared with controls ($3,862), difference
of $6,396, P < 0.0001. Outpatient services accounted for 34%,
inpatient services for 28%, and drug costs for 27% of epilepsy
patients’ annual direct costs. Among epilepsy patients, non-
epilepsy costs accounted for $8201 (80%) on average and
epilepsy-related costs (i.e., costs for antiepileptic drugs, claims
with an epilepsy or convulsions diagnosis, neurology visits, and
selected diagnostic procedures) accounted for $2057 (20%).
Approximately 13% ($1047) of non-epilepsy costs were attrib-
utable to mental health-related expenditures. CONCLUSIONS:
Patients with epilepsy had signiﬁcantly higher costs compared
with matched controls. The excess costs of epilepsy patients are
underestimated when looking only at epilepsy-related costs.
Epilepsy-related costs represented 20% of the annual direct costs
of epilepsy patients and almost one-third of the difference in costs
between epilepsy patients and controls.
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OBJECTIVES: A national multicentre retrospective study
(EPIZOD) based on medical records review was conducted
among a sample of general practitioners, dermatologists, neu-
rologists and anti-pain centers. Main EPIZOD objectives were
to estimate annual incidence of Herpes Zoster (HZ) and the
proportion of patients developing Post-Herpetic Neuralgia
(PHN) in France. PHN was deﬁned as “persistence of pain at
least one month after rash onset”. An economic study was
carried out in a sample of patients included in EPIZOD to
estimate costs associated with HZ and PHN management in
patients aged more than 50 in France. METHODS: Costs of
health resources utilization, including consultations, examina-
tions, treatments (i.e. drugs and non-pharmacological treat-
ments), hospitalizations and sick leaves, were valued according
to ofﬁcial tariffs and weighted by patients’ treatment patterns.
Estimations were calculated according to both Third Party
Payer (TPP) and societal perspectives. RESULTS: Among 862
HZ and 412 PHN patients included in EPIZOD, 108 and 88
patients, respectively, were recruited for the economic study.
Mean cost per HZ case was estimated to be €182.92 for TPP
and €346.78 for the society. Each PHN case was assessed to
cost on average €339.84 and €555.56 respectively. Main costs
drivers for TPP were treatments (about 50% of total costs),
followed by hospitalizations and medical consultations (about
20% each). Based on EPIZOD incidence estimations, annual
cost associated with HZ and PHN management would reach
€61.0 million for TPP and €108.5 million for the society. CON-
CLUSIONS: This study suggests that HZ and PHN are costly
diseases in France. In this context, our ﬁndings will be useful for
policymakers when assessing HZ and PHN control measures,
including the introduction of a vaccine.
PND13
ALZHEIMER’S DISEASE PRESCRIPTION MEDICATION COSTS:
2004–2005
Anderson K
Uniformed Services University of the Health Sciences, Bethesda, MD,
USA
OBJECTIVES: Alzheimer’s disease is a chronic, progressive
disease, characterized by deterioration of cognitive function. The
prevalence rate of Alzheimer’s disease is 10 percent in people
over the age of 70, and 40 percent for people over age 90. There
is no cure for Alzheimer’s disease therefore the goal of treatment
is to control the signs and symptoms of the disease through
prescription medications. At the national level, research is
lacking in the area of prescription medication costs for Alzhe-
imer’s disease. The objectives of this study were to estimate the
number and cost of prescription medications for Alzheimer’s
disease in the United States. METHODS: The Medical Expendi-
tures Panel Survey is a nationally representative sample of the
non-institutionalized, civilian population in the United States.
Data from the 2004–2005 Medical Expenditures Panel Survey
were used to estimate the cost of prescription medications for
Alzheimer’s disease. To test for a difference between costs of
prescription medications for gender, a t-test was used. A series of
one-way ANOVA analyses were used with each of the remaining
demographic variables (age, marital status, income and region of
residence) serving as the independent variable and the cost of
Alzheimer’s prescription medications as the dependent variable.
RESULTS: Over 1.9 million people reported having Alzheimer’s
disease in 2004 and 2005. Over the two year period, these
patients reported having over 10 million prescriptions ﬁlled for
Alzheimer’s medications at a cost of over $1.3 billion in U.S.
dollars. CONCLUSIONS: The most rapidly growing segment of
the population by the year 2030 will be people over the age of 85.
Because life expectancy is increasing and the risk of developing
Alzheimer’s increases with age, this cost of prescription medica-
tions estimation has both current and future relevance for health
care insurers, providers, administrators, policy makers and
Alzheimer’s patients.
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OBJECTIVES: CF patients need specialized long-term medica-
tion. In order to support lung function inhalable pharmaceuticals
like bronchodilators, mucolytica or anti-inﬂammatory drugs are
used. Oral or inhalable antibiotic therapy is especially important
for patients whose lung has a chronic colonization with germs. In
case of pancreatic insufﬁciency digestive enzymes have to be
substituted and patients need an additional supplement of vita-
mins as well as high caloric food. All of these aspects lead to high
medication in CF patients. Hence, aim of this work is to analyse
medication mixtures and related costs for CF in Germany.
METHODS: Medication data was evaluated in seven different
outpatient CF centres. Data was recorded via medication lists by
the physicians reporting name of medication, dosage and phar-
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